2-chloro-6-ethyl-4-trifluoromethylpyridine | 1251910-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-6-ethyl-4-trifluoromethylpyridine
• 英文别名: Pyridine, 2-chloro-6-ethyl-4-(trifluoromethyl)-；2-chloro-6-ethyl-4-(trifluoromethyl)pyridine
• CAS: 1251910-13-0
• 化学式: C₈H₇ClF₃N
• 分子量: 209.598
• InChiKey: KMGQHRYGNUTNRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  乙基溴化镁 、 2,6-二氯-4-三氟甲基吡啶 在 iron(III) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 1.3h， 生成 2-chloro-6-ethyl-4-trifluoromethylpyridine
  参考文献：
  名称：

  METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE

  摘要：

  本发明涉及一种用于制备2-卤代-6-取代-4-三氟甲基吡啶的方法。具体而言，本发明提供了一种制备由式(I)表示的2-卤代-6-取代-4-三氟甲基吡啶的方法：其中X是氯原子、溴原子或碘原子；R是烷基、烯基、炔基、苯基（可能被A取代）、苄基（可能被A取代）或环烷基；A是烷基、烷氧基、氟原子或氯原子；所述方法包括允许由式(II)表示的2,6-二卤代-4-三氟甲基吡啶：其中X如上定义，和由式(III)表示的格氏试剂：RMgX，在溶剂存在下相互反应。

  公开号：

  US20120035372A1

文献信息

• [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2019148005A1

  公开（公告）日：2019-08-01

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

  揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统，治疗适合免疫系统调节的疾病，并用于体内、体外或体外细胞的治疗。
• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE
  申请人：Newgen Therapeutics, Inc.

  公开号：US20170057984A1

  公开（公告）日：2017-03-02

  The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
• METHOD FOR PRODUCING 2-HALOGENO-6-SUBSTITUTED-4-TRIFLUOROMETHYLPYRIDINE
  申请人：IKEGUCHI Masahiko

  公开号：US20120035372A1

  公开（公告）日：2012-02-09

  The present invention relates to a process of a process for producing a 2-halogeno-6-substituted-4-trifluoromethylpyridine. Specifically, the present invention provides a process for producing a 2-halogeno-6-substituted-4-trifluoromethylpyridine represented by the formula (I): in which X is a chlorine atom, a bromine atom, or an iodine atom; R is alkyl, alkenyl, alkynyl, phenyl which may be substituted with A, benzyl which may be substituted with A, or cycloalkyl; and A is alkyl, alkoxy, a fluorine atom, or a chlorine atom, which comprises allowing a 2,6-dihalogeno-4-trifluoromethylpyridine represented by the formula (II): in which X is defined above, and a Grignard reagent represented by the formula (III): RMgX, in which R and X are defined above, to react with each other in the presence of a solvent.

  本发明涉及一种用于制备2-卤代-6-取代-4-三氟甲基吡啶的方法。具体而言，本发明提供了一种制备由式(I)表示的2-卤代-6-取代-4-三氟甲基吡啶的方法：其中X是氯原子、溴原子或碘原子；R是烷基、烯基、炔基、苯基（可能被A取代）、苄基（可能被A取代）或环烷基；A是烷基、烷氧基、氟原子或氯原子；所述方法包括允许由式(II)表示的2,6-二卤代-4-三氟甲基吡啶：其中X如上定义，和由式(III)表示的格氏试剂：RMgX，在溶剂存在下相互反应。